Candel Therapeutics Shares Are Trading Higher After the Company Received FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer.
Candel Therapeutics Shares Are Trading Higher After the Company Received FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer.
在Candel Therapeutics獲得美國食品藥品管理局用於治療胰腺癌的 CAN-2409 孤兒藥認定後，該公司股價走高。
Candel Therapeutics Shares Are Trading Higher After the Company Received FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer.
在Candel Therapeutics獲得美國食品藥品管理局用於治療胰腺癌的 CAN-2409 孤兒藥認定後，該公司股價走高。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。